Medtronic plc (MDT)
2025-07-25 | 2025-01-24 | 2024-10-25 | 2024-07-26 | |
|---|---|---|---|---|
| Net sales | 8,578 | 8,292 | 8,403 | 7,915 |
| Research and development expense | 726 | 675 | 697 | 676 |
| Other operating expense, net | -70 | 5 | 34 | -1 |
| Certain litigation charges, net | 27 | 22 | - | 81 |
| Cost of products sold, excluding amortization of intangible assets | 3,001 | 2,779 | 2,946 | 2,761 |
| Amortization of intangible assets | 459 | 416 | 413 | 414 |
| Restructuring charges, net | 45 | 43 | 30 | 47 |
| Selling, general, and administrative expense | 2,806 | 2,717 | 2,757 | 2,655 |
| Operating profit | 1,445 | 1,646 | 1,595 | 1,278 |
| Interest expense, net | 176 | 179 | 209 | 167 |
| Other non-operating income, net | 33 | 72 | 173 | 157 |
| Income before income taxes | 1,302 | 1,540 | 1,559 | 1,268 |
| Income tax provision | 255 | 237 | 281 | 220 |
| Net income | 1,047 | 1,303 | 1,278 | 1,049 |
| Net income attributable to noncontrolling interests | 7 | 9 | 9 | 6 |
| Net income attributable to medtronic | 1,040 | 1,294 | 1,270 | 1,042 |
| Basic earnings per share (in dollars per share) | 0.81 | 1.01 | 0.99 | 0.81 |
| Basic weighted average shares outstanding (in shares) | 1,281,600,000 | 1,282,400,000 | 1,282,400,000 | 1,293,300,000 |
| Diluted earnings per share (in dollars per share) | 0.81 | 1.01 | 0.99 | 0.8 |
| Diluted weighted average shares outstanding (in shares) | 1,287,100,000 | 1,286,200,000 | 1,286,900,000 | 1,296,500,000 |